Phase 2 trial reveals Lixisenatide may reduce motor disability in Parkinson’s patients Post author: Post published:April 18, 2024 Post category:uncategorized A trial of lixisenatide to assess its effects in early Parkinson’s disease. You Might Also Like Lost in the mix of Medicaid ‘unwinding’: Kentucky cut off her health care over a clerical error November 21, 2023 Gut bacteria help ease chemotherapy side effects and aid recovery May 21, 2025 NYU Langone Health continues streak of “A” safety rating from Leapfrog November 17, 2024
Lost in the mix of Medicaid ‘unwinding’: Kentucky cut off her health care over a clerical error November 21, 2023